GLP1R and Mental deterioration: In this proof-of-concept study, we tested the hypothesis that the treatment with the long-acting GLP-1 RA exenatide could prevent or slow down the progression of cognitive decline in MCI subjects, measured with the ADAS-Cog score, when compared to no active intervention.